Stanford, California 94305


Purpose:

This study is designed to investigate the treatment response of lymphedema, of the upper or lower extremity, during clinical, pharmacologic treatment of lymphedema with oral ketoprofen. Correlation of clinical responses (changes in limb volume and skin thickness) with changes in the inflammasome will help to define the molecular substrate of treatment response.


Study summary:

Patients presenting to the Investigator's Clinic for evaluation and treatment of (upper or lower extremity) lymphedema, will be assessed for their suitability (of low risk) for medical treatment with ketoprofen. If there are no contra-indications to taking ketoprofen, after discussion of FDA warnings, including provision of a written copy of the FDA language to the patient, and with the recommendation to discuss with the primary physician-of-record, patients will be provided with a prescription for ketoprofen 200 mg daily (one capsule taken orally, once daily) or if obtained from a compound pharmacy, ketoprofen 210 mg daily (one capsule taken orally, once daily). Participation in this study will be offered. Two study visits, at baseline and month 6 are required. Measurements (circumferential and skin thickness) and a blood sample will be taken at each study visit. The investigators will try to determine how ketoprofen affects the body tissue by obtaining blood samples and measurements, before starting treatment and at month 6.


Criteria:

Inclusion Criteria: - Participants with a history of acquired lymphedema - Stage 1, 2, or 3 - 18-75 years - Clinical use of ketoprofen for lymphedema Exclusion Criteria: - Active cancer, infection, bleeding tendency, inflammatory disease and/or taking anti-inflammatory or anti-leukotriene medication will be excluded. - Pregnant or lactating females - Inability to take ketoprofen (contra-indicated, e.g patients with known CV, GI, renal, hepatic disease). - Other severe acute or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation, may interfere with interpretation of study results, and in the judgement of the investigator, would make the participation inappropriate for entry into this study.


NCT ID:

NCT03783715


Primary Contact:

Principal Investigator
Stanley G Rockson
Stanford University

Leslie Roche, BSN
Phone: 650-723-1396
Email: lesroche@stanford.edu


Backup Contact:

N/A


Location Contact:

Stanford, California 94305
United States

Leslie Roche, RN
Phone: 650-723-1396
Email: lesroche@stanford.edu

Site Status: Recruiting


Data Source: ClinicalTrials.gov

Date Processed: August 31, 2019

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.


Click to view Full Listing

If you would like to be contacted by the clinical trial representative please fill out the form below.